FDA Approves Updated COVID-19 Vaccines for 2026-2027 Respiratory Season
The U.S. Food and Drug Administration (FDA) has approved updated formulations of COVID-19 vaccines from Moderna, Pfizer-BioNTech, and Novavax for the 2026-2027 respiratory virus season. These vaccines are reformulated to target the JN.1-lineage XFG subvariant of SARS-CoV-2.
Want more?
Open NewsSnap.ai for the full app experience, including audio, personalization, and more news tools.